Fluzoparib combined with Apatinib

DRUG2 trials

Sponsors

Tianjin Medical University Second Hospital, Jiangsu HengRui Medicine Co., Ltd.

Conditions

Advanced CancerMetastatic Castration Resistant Prostate Cancer

Phase 1

Treatment of Carrying TP53 Harmful Mutations

Tianjin Medical University Second HospitalAdvanced Cancer

Start: 2019-07-01End: 2020-06-01Target: 60Updated: 2019-04-25

Phase 2

A Trial of SHR3162 Combined With Apatinib Mesylate Tablets or SHR3162 Monotherapy in Patients With Metastatic Castration Resistant Prostate Cancer

CompletedNCT04869488

Jiangsu HengRui Medicine Co., Ltd.Metastatic Castration Resistant Prostate Cancer

Start: 2021-07-19End: 2023-02-14Updated: 2025-01-24